We are contrasting Clovis Oncology Inc. (NASDAQ:CLVS) and Denali Therapeutics Inc. (NASDAQ:DNLI) on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clovis Oncology Inc.	95.39M	11.39	368.01M	-7.06	0.00
Denali Therapeutics Inc.	129.16M	20.12	36.24M	-1.45	0.00

Table 1 shows the gross revenue, earnings per share and valuation for Clovis Oncology Inc. and Denali Therapeutics Inc.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of Clovis Oncology Inc. and Denali Therapeutics Inc.

	Net Margins	Return on Equity	Return on Assets
Clovis Oncology Inc.	-385.80%	-95.6%	-35.6%
Denali Therapeutics Inc.	-28.06%	-27.9%	-24.7%

Liquidity

Clovis Oncology Inc.’s Current Ratio and Quick Ratio are 9 and 8.5 respectively. The Current Ratio and Quick Ratio of its competitor Denali Therapeutics Inc. are 12.1 and 12.1 respectively. Denali Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Clovis Oncology Inc.

Analyst Ratings

The Ratings and Recommendations for Clovis Oncology Inc. and Denali Therapeutics Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Clovis Oncology Inc.	0	3	4	2.57
Denali Therapeutics Inc.	0	0	0	0.00

The upside potential is 48.08% for Clovis Oncology Inc. with consensus price target of $30.43.

Institutional & Insider Ownership

The shares of both Clovis Oncology Inc. and Denali Therapeutics Inc. are owned by institutional investors at 0% and 84.5% respectively. Insiders owned roughly 0.5% of Clovis Oncology Inc.’s shares. On the other hand, insiders owned about 0.1% of Denali Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Clovis Oncology Inc.	16.29%	16.8%	75.58%	-18.96%	-49.31%	64.92%
Denali Therapeutics Inc.	-0.05%	15.48%	14.34%	22.14%	2.04%	6.53%

For the past year Clovis Oncology Inc. has stronger performance than Denali Therapeutics Inc.

Summary

Denali Therapeutics Inc. beats Clovis Oncology Inc. on 9 of the 11 factors.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier; and a clinical collaboration with Bristol-Myers Squibb Company to evaluate combination of Opdivo (Nivolumab) and Rubraca (rucaparib) in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.